Eran van Veldhuisen
Overview
Explore the profile of Eran van Veldhuisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rompen I, Stoop T, van Roessel S, van Veldhuisen E, Janssen Q, Alseidi A, et al.
Ann Surg
. 2025 Jan;
PMID: 39886770
Aim: To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of...
2.
Stoop T, Sugawara T, Oba A, Feld I, van Roessel S, van Veldhuisen E, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39847363
Importance: The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy...
3.
Michiels N, Doppenberg D, Groen J, van Veldhuisen E, Bonsing B, Busch O, et al.
Ann Surg Oncol
. 2023 Feb;
30(6):3455-3463.
PMID: 36774435
Background: Determining the resectability of pancreatic cancer with vascular involvement on preoperative computed tomography imaging remains challenging, especially following preoperative chemotherapy and chemoradiotherapy. Intraoperative ultrasound (IOUS) may provide real-time additional...
4.
van Veldhuisen E, Klompmaker S, Janssen Q, Abu Hilal M, Alseidi A, Balduzzi A, et al.
Ann Surg Oncol
. 2022 Dec;
30(3):1463-1473.
PMID: 36539580
Background: Preoperative FOLFIRINOX chemotherapy is increasingly administered to patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) to improve overall survival (OS). Multicenter studies reporting on the impact...
5.
Stoop T, van Veldhuisen E, van Rijssen L, Klaassen R, Gurney-Champion O, de Hingh I, et al.
Langenbecks Arch Surg
. 2022 Oct;
407(8):3487-3499.
PMID: 36242618
Background: Restaging of locally advanced pancreatic cancer (LAPC) after induction chemotherapy using contrast-enhanced computed tomography (CE-CT) imaging is imprecise in evaluating local tumor response. This study explored the value of...
6.
Outcomes of Irreversible Electroporation for Perihilar Cholangiocarcinoma: A Prospective Pilot Study
Franken L, van Veldhuisen E, Ruarus A, Coelen R, Roos E, van Delden O, et al.
J Vasc Interv Radiol
. 2022 Mar;
33(7):805-813.e1.
PMID: 35346858
Purpose: To investigate the safety and efficacy of percutaneous or open irreversible electroporation (IRE) in a prospective cohort of patients with locally advanced, unresectable perihilar cholangiocarcinoma (PHC). Materials And Methods:...
7.
Strijker M, van Veldhuisen E, van der Geest L, Busch O, Bijlsma M, Haj Mohammad N, et al.
Biomarkers
. 2021 Mar;
26(4):325-334.
PMID: 33663300
Background: Identification of metastatic pancreatic cancer (mPC) patients with the worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a...
8.
Agnass P, Rodermond H, Zweije R, Sijbrands J, Vogel J, van Lienden K, et al.
Sensors (Basel)
. 2020 Nov;
20(21).
PMID: 33142821
Electric permeabilization of cell membranes is the main mechanism of irreversible electroporation (IRE), an ablation technique for treatment of unresectable cancers, but the pulses also induce a significant temperature increase...
9.
van Roessel S, van Veldhuisen E, Klompmaker S, Janssen Q, Abu Hilal M, Alseidi A, et al.
JAMA Oncol
. 2020 Sep;
6(11):1733-1740.
PMID: 32910170
Importance: The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. Objective: To assess the association...
10.
van Veldhuisen E, Vroomen L, Ruarus A, Derksen T, Busch O, de Jong M, et al.
J Vasc Interv Radiol
. 2020 Aug;
31(10):1600-1608.
PMID: 32861569
Purpose: To compare survival after CT-guided percutaneous irreversible electroporation (IRE) and folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) chemotherapy versus FOLFIRINOX only in patients with locally advanced pancreatic cancer (LAPC)....